Peregrine Pharmaceuticals (NASDAQ: PPHM) reported Q3 EPS of ($0.06), in-line with the analyst estimate of ($0.06). Revenue for the quarter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE